Journal Article Summary
The article discusses the treatment of acute severe ulcerative colitis (ASUC), a serious condition that poses significant challenges for healthcare providers. Despite advancements in therapies for inflammatory bowel diseases, patients with severe cases often experience limited success with current treatments. The study specifically compares two effective options for patients who do not respond to steroids: infliximab and cyclosporine. Understanding the effectiveness of these treatments is crucial for improving patient outcomes and guiding clinical decisions.
In the study, researchers conducted a randomized trial involving 270 patients from 52 hospitals, with participants divided equally between infliximab and cyclosporine. The primary outcome measured was quality-adjusted survival over three years, while secondary outcomes included quality of life, need for surgery, and cost-effectiveness. The results showed no significant difference in quality-adjusted survival between the two treatments, and the rates of colectomy were also similar. However, infliximab was associated with higher healthcare costs compared to cyclosporine.
The article notes several limitations in the trial design, such as the absence of important endpoints like mucosal healing and the influence of co-morbidities on quality of life measures. These factors may affect the accuracy of the findings regarding treatment efficacy. Patients should discuss these results and their treatment options with healthcare professionals, considering that individual responses to therapy can vary. Additionally, exploring personalized treatment strategies and ongoing monitoring may enhance outcomes for those suffering from ASUC.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Ananthakrishnan Ashwin N. Infliximab or Cyclosporine – Is The Final Answer In?. The lancet. Gastroenterology & hepatology 2016. DOI: 10.1016/S2468-1253(16)30016-4. PMID: 28404107. PMCID: PMC5651678.
Featured Pill Pals Product
Cyclosporine Eye Drops 0.05% --- 0.4 ML --- Pack of 30 --- Generic For Restasis --- Apotex
Cyclosporine Eye Drops 0.05% — 0.4 ML — Pack of 30 — Generic For Restasis — Apotex is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
